These genes are frequently altered, such as PIK3CA mutation or amplification in up to 30% ovarian cancer patients, while PTEN expression was lost in up to 40% of patients (Campbell et al., 2004; Kurose et al., 2001). This evidence concerns the gene PTEN and ovarian carcinoma.